80047327EM - Novel Targeted Agents in the Management of Recurrent Advanced Ovarian Cancer_EM



Date & Location
Thursday, May 23, 2019, 12:00 AM - Saturday, May 23, 2020, 11:59 PM

Target Audience
Specialties - Nurse Practitioner, Ob/Gyn, Oncology, Physician Assistant

Overview

An enduring grand round presentation focusing on new therapeutic options for managing recurrent advanced ovarian cancer.

This educational initiative will:

  • Review the the role of angiogenesis inhibitors in the management of recurrent advanced ovarian cancer.
  • Discuss the role of homologous recombination deficiency in the development of recurrent advanced ovarian cancer.
  • Describe the mechanism of action, efficacy, and safety of PARP inhibitors approved to treat advanced ovarian cancer.
  • Outline the management of patients with recurrent advanced ovarian cancer by incorporating angiogenesis inhibitors or PARP inhibitors into a management program.
  • Outline strategies for engaging patients about PARP inhibitor use to promote adherence to therapy.

This activity is intended for oncologists, gynecologists, and other clinicians including nurse practitioners (NPs), physician assistants (PAs), and nurses who encounter patients with ovarian cancer. There are no prerequisites for this activity.

https://www.cmecorner.com/programs.asp?audience=&ProductID=2326&partner=JHU

The release date: Thursday, May 23, 2019
The expiration date: May 23, 2020



Objectives
After participating in this activity, the participant will demonstrate the ability to:

  1. Discuss the role of angiogenesis inhibitors in the management of recurrent advanced ovarian cancer.
  2. Discuss the role of homologous recombination (HR) deficiency in the development of recurrent advanced ovarian cancer.
  3. Describe the mechanism of action, efficacy, and safety of PARP inhibitors approved to treat advanced ovarian cancer.
  4. Outline the management of patients with recurrent advanced ovarian cancer by incorporating angiogenesis inhibitors or PARP inhibitors into a management program.
  5. Outline strategies for engaging patients about PARP inhibitor use to promote adherence to therapy.

Accreditation

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physicians 
The Johns Hopkins University School of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity. 

Other Credits 
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

 

Keywords: ONLINE